Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

Usmani, Saad Z. ^{[2
]}

Quach, Hang ^{[3
]}

Dimopoulos, Meletios-Athanasios ^{[4
]}

Fonseca, Rafael ^{[5
]}

McFadden, Ian ^{[6
]}

Yusuf, Akeem ^{[6
]}

Khurana, Monica ^{[6
]}

Obreja, Mihaela ^{[6
]}

Spencer, Andrew ^{[7
]}

机构：

[1] Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[3] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[4] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, Athens, Greece

[5] Mayo Clin, Scottsdale, AZ USA

[6] Amgen Inc, Thousand Oaks, CA 91320 USA

[7] Monash Univ, Alfred Health, Clayton, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-204

引用

页码：S150 / S151

页数：2

共 50 条

[31] Efficacy and Safety of Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd) in Patients With Relapsed Multiple Myeloma By Prior Autologous Stem Cells Transplantation: Secondary Analysis From the Phase 3 Endeavor Study (NCT01568866)
Mateos, M. -V.
Knop, S.
Fermand, J. -P.
Hajek, R.
Ludwig, H.
Feng, S.
Mohamed, N.
Gillenwater, H. H.
Iskander, K.
Goldschmidt, H.
BONE MARROW TRANSPLANTATION, 2016, 51 : S17 - S18
[32] CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRD) IN PATIENTS WITH MULTIPLE MYELOMA REFRACTORY TO FIRST LINE THERAPY WITH VTD: FOCUS ON STEM CELL MOBILIZATION AND OVERALL RESPONSE RATE BEFORE AUTOLOGOUS TRANSPLANT
Trastulli, F.
Avilia, S.
Vitiello, S.
Scairati, G.
Esposito, M.
Iannalfo, M.
D'Agostino, F.
De Fazio, L.
Fiumarella, A.
Fatigati, C.
Pisano, I.
Capone, M.
Vitagliano, O.
Izzo, B.
Pane, F.
Catalano, L.
HAEMATOLOGICA, 2021, 106 (10) : 167 - 167
[33] Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
Kubicki, Tadeusz
Dytfeld, Dominik
Wrobel, Tomasz
Jamroziak, Krzysztof
Robak, Pawel
Czyz, Jaroslaw
Tyczynska, Agata
Druzd-Sitek, Agnieszka
Giannopoulos, Krzysztof
Szczepaniak, Tomasz
Lojko-Dankowska, Anna
Matuszak, Magdalena
Gil, Lidia
Pula, Bartosz
Rybka, Justyna
Majcherek, Maciej
Usnarska-Zubkiewicz, Lidia
Szukalski, Lukasz
Zaucha, Jan Maciej
Mikulski, Damian
Czabak, Olga
Lahoud, Oscar B.
Stefka, Andrew
Derman, Benjamin A.
Jakubowiak, Andrzej J.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (05) : 792 - 802
[34] Carfilzomib, Lenalidomide and Dexamethasone (KRD) Therapy Post Autologous Stem- Cell Transplantation (ASCT): Real-World Data in Multiple Myeloma Patients Eligible for Second ASCT
Vaitekenaite, Vilmante
Klimiene, Indre
Peceliunas, Valdas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S278 - S279
[35] INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
Zimmerman, T. M.
Griffith, K.
Jasielec, J. K.
Rosenbaum, C. A.
McDonnell, K.
Marin, J.
Bakker, J.
Berdeja, J. G.
Vij, R.
Jakubowiak, A. J.
HAEMATOLOGICA, 2014, 99 : 103 - 103
[36] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
Zimmerman, Todd M.
Griffith, Kent A.
Jasielec, Jagoda
Rosenbaum, Cara Ann
McDonnell, Kathryn
Waite-Marin, Jessica
Berdeja, Jesus G.
Raje, Noopur S.
Reece, Donna Ellen
Vij, Ravi
Alonge, Mattina
Rosebeck, Shaun
Gurbuxani, Sandeep
Faham, Malek
Kong, Katherine A.
Levy, Joan
Jakubowiak, Andrzej J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study
Roussel, Murielle
Lauwers-Cances, Valerie
Robillard, Nelly
Belhadj, Karim
Facon, Thierry
Garderet, Laurent
Escoffre, Martine
Pegourie, Brigitte
Benboubker, Lotfi
Caillot, Denis
Fohrer, Cecile
Moreau, Philippe
Leleu, Xavier
Avet-Loiseau, Herve
Attal, Michel
BLOOD, 2016, 128 (22)
[38] Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation - a retrospective analysis
Sterrett, Russell
Figueiredo, Amarilis
Mallick, Ranjeeta
Kekre, Natasha
Atkins, Harold
McCurdy, Arleigh
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (04) : 437 - 442
[39] Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report
Ryutaro Taenaka
Sakurako Shimokawa
Ayako Katayama
Toshihiko Nagao
Teppei Obara
Naoaki Nishimura
Atsushi Tsujimoto
Kentaro Kohno
Kenichi Aoki
Ryosuke Ogawa
Journal of Medical Case Reports, 16
[40] Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report
Taenaka, Ryutaro
Shimokawa, Sakurako
Katayama, Ayako
Nagao, Toshihiko
Obara, Teppei
Nishimura, Naoaki
Tsujimoto, Atsushi
Kohno, Kentaro
Aoki, Kenichi
Ogawa, Ryosuke
JOURNAL OF MEDICAL CASE REPORTS, 2022, 16 (01)

← 1 2 3 4 5 →